COMMUNIQUÉS West-GlobeNewswire

InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
22/06/2026
● The funding includes investments commitments from key shareholders of the Company, including the Company’s CEO Alexander Rabinovich, as well as leading pharma-focused hedge funds, including Bennu Pharma Fund Ltd., [...]
Novo Nordisk A/S - share repurchase programme
22/06/2026
Bagsværd, Denmark, 22 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Parexel Launches Parexel Biotech Incubator to Connect Early-Stage Innovation with Clinical Development Expertise
22/06/2026
Initiative creates new resource to support and accelerate early-stage therapeutics companies Parexel forms inaugural partnership with Durham-based Cape Fear BioCapital to connect incubator to a seed-stage venture [...]
INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure
22/06/2026
23% revenue growth, elimination of all Series C-2 Preferred Stock and warrant liabilities, and a strengthened balance sheet Growth reflects both organic clinic initiatives and acquisition contribution from Family [...]
Marius Pharmaceuticals Applauds FDA’s Proposed Testosterone Labeling Updates as a Turning Point for Men’s Health
22/06/2026
The FDA’s second major labeling update in 16 months — after its February 2025 removal of the cardiovascular boxed warning — marks a historic modernization of how testosterone therapy is prescribed, bringing labeling in [...]
Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain
22/06/2026
PHOENIX, June 22, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company") , a clinical-stage biotechnology company advancing regenerative medicine [...]
Weight Watchers to Support the American Heart Association’s Healthy Living BEYOND Weight Study
22/06/2026
Weight Watchers helps members achieve lasting weight loss through medication, personalized nutrition, and community support. As part of its collaboration with the American Heart Association, Weight Watchers is [...]
CurePSP Expands Grant Program with $155,000 Investment in Studying Care for Rare Neurological Diseases
22/06/2026
NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) -- CurePSP announced the latest recipients of the Collaborative Approaches to Resources, Education and Support (CARES) grants, awarding a total of $155,000 to four projects [...]
BrewDog Bars Draw Record Fan Turnout as Global Tournament Fever Drives Double-Digit Growth
22/06/2026
Fans pack BrewDog bars for world-class football, ice-cold beer, American craft favourites, and a cool escape from the summer heat ELLON, Scotland, June 22, 2026 (GLOBE NEWSWIRE) -- Scottish brewer BrewDog , owned by [...]
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
22/06/2026
RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026 [...]
Nura Bio Completes $73.8M Series B Financing and Advances Pipeline of SARM1 Inhibitors
22/06/2026
– Series B proceeds will fund clinical proof-of-biology studies of SARM1 inhibitors – First patient dosed in Phase 1b/2a ALS study with NB-4746, an oral, brain-penetrant SARM1 inhibitor – Dosing initiated in a first-in- [...]
Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers
22/06/2026
Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment options DAREON®-Lung-1 and DAREON®-NEC-1 will evaluate obrixtamig as a DLL3 biomarker- [...]
Clariane has launched a proposed offering of €333 million of undated deeply subordinated hybrid notes to refinance its ODIRNANE
22/06/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Clariane has [...]
Clariane annonce le lancement d’une offre de 333 millions d’euros d’obligations hybrides à durée indéterminée subordonnées de dernier rang en vue du refinancement de ses ODIRNANE
22/06/2026
NE PAS DIFFUSER, PUBLIER OU DISTRIBUER, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE, AU CANADA, AU JAPON OU EN AUSTRALIE, OU DANS TOUTE AUTRE JURIDICTION OU IL EST ILLÉGAL DE DIFFUSER, DE PUBLIER OU DE [...]
Oxford BioTherapeutics' Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3
22/06/2026
First patients dosed with BI 3820768 (OB33), marking third programme from the Oxford BioTherapeutics (OBT)-Boehringer Ingelheim collaboration to enter clinical development Obrixtamig reaches late-stage development [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
22/06/2026
COPENHAGEN, Denmark, June 22, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to [...]
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
22/06/2026
Sanofi a ppoints Paulo Fontoura as Global Head of R&D Paris , June 22 , 2026 . Sanofi today announced the appointment of Paulo F o ntoura , MD, PhD, FAAN, as Executi v e Vice President, Global Head of Research [...]
CARBIOS presents the results of its Annual General Meeting of June 18, 2026
22/06/2026
Clermont-Ferrand (France), June 22, 2026 (7:45 am CEST). CARBIOS , (Euronext Growth Paris: ALCRB), announces the results of its Annual Ordinary and Extraordinary General Meeting held on June 18, 2026. Shareholders [...]
Communiqué de presse : Sanofi nomme Paulo Fontoura à la tête de sa R&D
22/06/2026
Sanofi nomme Paulo Fontoura à la tête de sa R&D Paris , 22 juin 2026. Sanofi annonce la nomination du Dr Paulo Fontoura au poste de Vice-Président Exécutif, Responsable mondial de la Recherche & Développement [...]

Pages